These in vitro results in various cell models (breast and gastric cancer cell lines, breast PDX primary culture), together with our published observations in vivo with PDXs and HER2 breast carcinoma patients [12], suggest that the GSDMB over-expression would induce resistance to trastuzumab as well as lapatinib. Here, ERBB2 is linked to gastric cancer.